Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.

Date publication

février 2019

Journal

Current opinion in neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
de Seze J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30562266

Résumé

Neuromyelitis optica spectrum disorder (NMOSD) is a severe inflammatory disease of the central nervous system, particularly characterized by disabling episodes of optic neuritis and longitudinally extensive transverse myelitis. The pathogenic characteristic is the presence of antiaquaporin 4 antibodies (AQP4-Abs) in the cerebrospinal fluid and serum of most of the affected patients. However, a proportion of the patients (around 20-30%) that have a typical phenotype of NMO are seronegative for AQP4-Abs.

Référence

Curr. Opin. Neurol.. 2019 Feb;32(1):111-114